We are happy to announce today the opening of a Security Token Offering (STO) on the EDSX platform, after raising a record €2M on Capital cell.
Capital Cell is the the 1st European platform for participative financing dedicated to healthcare. We have raised 2 millions euros in less than 24h! By Capital Cell’s own admission, the hype surrounding HCS Pharma is unprecedented.
This fundraising campaign is part of a global approach whose objective is to provide HCS Pharma with the means for its long-term development.
Following the STO, HCS Pharma will focus on its planned listing on the Frankfurt Stock Exchange in Q3 2022 and on the Nasdaq in New York within the next 12 months. The tokens acquired through the STO will be converted into shares of the company as soon as the listing is effective.
This listing will also free up the USD 20 million financing secured from an American family office.
To learn more, go to: http://invest.hcs-pharma.com/